Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

teva pharma ag - glatiramerum - soluzione iniettabile in siringa preriempita - glatirameri acetas 20 mg corresp. glatiramerum 18 mg, mannitolum, aqua ad iniectabile q.s. ad solutionem pro 1 ml. - multiple sklerose - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

teva pharma ag - glatiramerum - soluzione iniettabile in siringa preriempita - glatirameri acetas 40 mg corresp. glatiramerum 36 mg, mannitolum, aqua ad iniectabile q.s. ad solutionem pro 1 ml. - multiple sklerose - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

takeda pharma ag - mifamurtidum - polvere per concentrato per la preparazione di una infusionsdispersion - praeparatio cryodesiccata: mifamurtidum natricum 4 mg corresp. mifamurtidum 3.93 mg, 1,2-dioleoyl-sn-glycero-3-phosphoserinum natricum, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholinum, pro vitro corresp. natrium 8.13 - 9.9 mg. - trattamento del osteosarkoms - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

viatris pharma gmbh - glatiramerum - soluzione iniettabile in siringa preriempita - glatirameri acetas 20 mg corresp. glatiramerum 18 mg, mannitolum, aqua ad iniectabile q.s. ad solutionem pro 1 ml. - multiple sklerose - synthetika

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

mylan s.p.a. - glatiramer acetato - glatiramer acetato

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

teva pharma ag - glatiramerum - soluzione iniettabile in penna preriempita - glatirameri acetas 40 mg corresp. glatiramerum 36 mg, mannitolum, aqua ad iniectabile q.s. ad solutionem pro 1 ml. - multiple sklerose - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

viatris pharma gmbh - glatiramerum - soluzione iniettabile in siringa preriempita - glatirameri acetas 40 mg corresp. glatiramerum 36 mg, mannitolum, aqua ad iniectabile q.s. ad solutionem pro 1 ml. - multiple sklerose - synthetika

Unione Europea - italiano - EMA (European Medicines Agency)

accord healthcare s.l.u. - plerixafor - multiple myeloma; hematopoietic stem cell transplantation - immunostimolanti, - adult patientsplerixafor accord is indicated in combination with granulocyte-colony stimulating factor (g-csf) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma or multiple myeloma whose cells mobilise poorly (see section 4. paediatric patients (1 to less than 18 years)plerixafor accord is indicated in combination with g-csf to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma or solid malignant tumours, either:- pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with g-csf (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or- who previously failed to collect sufficient haematopoietic stem cells (see section 4.

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

tillomed italia srl - plerixafor - plerixafor

Unione Europea - italiano - EMA (European Medicines Agency)

biovest europe ltd - dasiprotimut-t - linfoma, non hodgkin - sospensione iniettabile - il trattamento del linfoma non-hodgkins (fl),.